Most recent update: Monday, April 6, 2020 - 08:53

Bariatric News - Cookies & privacy policy

You are here

HERO registry

Banding associated with improved comorbidities

One-year data from 834 patients for efficacy analysis

According to the one-year results from the Helping Evaluate Reduction in Obesity (HERO) prospective registry, the LAP-BAND AP System (LBAP, Allergan) results in progressive weight loss and is associated with improvement and/or resolution of comorbid conditions. The system was also reported to be safe and well tolerated in patients. The outcomes were published in the Journal of the American College of Surgeons.

The study, which started in December 2009, has enrolled 1,106 patients and will report the changes in weight, waist and hip circumference, blood pressure, HbA1c, fasting glucose, lipid profile, concomitant medications and health-related quality of life.

The current paper reports the one-year data from 834 patients for efficacy analysis. After 12 months, the percentage of excess weight loss (mean) was 39.8 (22.3)%, the percentage of weight loss was 16.9 (9.0)%, and the decreased to 37.7 (7.0) from 45.1 (6.9) at baseline. Patients with type 2 diabetes mellitus or hypertension showed significant improvements at one-year post-LBAP (both p<0.005).

The most common device-related complications were port displacement (n=20 [1.8%]), pouch dilatation (n=12 [1.1%]), band slippage (n=7 [0.6%]), and band erosion (n=5 [0.5%]). A total of 18 (1.6%) patients had the device explanted.

The registry, sponsored by Allergan Medical, is an on-going five-year prospective, observational, international, multicentre registry prospectively assessing the efficacy and safety of LBAP in real-world settings at clinical centres located in North America, Europe, and Australia.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.